These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8619071)

  • 21. Felbamate.
    Med Lett Drugs Ther; 1993 Nov; 35(910):107-9. PubMed ID: 8232064
    [No Abstract]   [Full Text] [Related]  

  • 22. Felbamate-induced delayed anaphylaxis.
    O'Neil MG; Probst L; Patel S
    Ann Pharmacother; 1995 Apr; 29(4):430. PubMed ID: 7633024
    [No Abstract]   [Full Text] [Related]  

  • 23. Epilepsy: taming the seizures, dispelling the myths.
    Hingley AT
    FDA Consum; 1999; 33(1):28-32. PubMed ID: 10030144
    [No Abstract]   [Full Text] [Related]  

  • 24. Criteria for use of felbamate in adult, adolescent, and child inpatients and outpatients.
    Luer MS
    Am J Hosp Pharm; 1994 Jul; 51(13):1701-3; Quiz 1704-5. PubMed ID: 7942896
    [No Abstract]   [Full Text] [Related]  

  • 25. Felbamate: new preparation. May benefit multiresistant epileptic patients.
    Prescrire Int; 1998 Jun; 7(35):78-81. PubMed ID: 10342924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative analyses for antiepileptic drug trials.
    Pledger GW; Sahlroot JT
    Epilepsy Res Suppl; 1993; 10():167-74. PubMed ID: 8251092
    [No Abstract]   [Full Text] [Related]  

  • 27. [Autopsy case of aplastic anemia suspected to be caused by anticonvulsants].
    Nakaya Y; Kitagawa S; Takase S; Kawai K; Sawabu N
    Naika; 1971; 28(5):946-9. PubMed ID: 5140296
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiepileptic drugs in clinical development.
    Ramsay RE; Slater JD
    Epilepsy Res Suppl; 1993; 10():45-67. PubMed ID: 8251106
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacogenetics--the horizon.
    Kurth JH
    Rev Gastroenterol Disord; 2003; 3 Suppl 1():S3-8. PubMed ID: 12684583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Aplastic anemia associated with drug].
    Nara N
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():478-81. PubMed ID: 18074586
    [No Abstract]   [Full Text] [Related]  

  • 31. What's the problem with generic antiepileptic drugs?: a call to action.
    Berg MJ
    Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211
    [No Abstract]   [Full Text] [Related]  

  • 32. [The pharmacologic and clinical profile of the new anticonvulsant felbamate--an overview].
    Steinhoff BJ
    Fortschr Neurol Psychiatr; 1994 Oct; 62(10):379-88. PubMed ID: 8001894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New antiepileptic drugs: vagabatrin, lamotrigine and felbamate].
    Herranz JL; Arteaga R; Armijo JA
    Neurologia; 1994 Nov; 9(9):410-7. PubMed ID: 7811493
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hemopathies caused by drugs in children: aplastic anemia, agranulocytosis, megaloblastic anemia].
    Masera G; Baronciani D; Conti A; Jankovic M; Uderzo C
    Minerva Pediatr; 1978 Sep; 30(18):1463-72. PubMed ID: 703709
    [No Abstract]   [Full Text] [Related]  

  • 35. Phenobarbital-associated bone marrow aplasia: a case report and review of the literature.
    Focosi D; Kast RE; Benedetti E; Papineschi F; Galimberti S; Petrini M
    Acta Haematol; 2008; 119(1):18-21. PubMed ID: 18230962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
    Struve CT
    Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
    [No Abstract]   [Full Text] [Related]  

  • 37. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA proposes higher fees for drug approvals to cover postmarketing surveillance.
    Tanne JH
    BMJ; 2007 Jan; 334(7586):177. PubMed ID: 17255596
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug-bone marrow interactions.
    Berbatis CG; Hurley SF
    Med J Aust; 1987 Jul; 147(2):101. PubMed ID: 3600446
    [No Abstract]   [Full Text] [Related]  

  • 40. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.